CANNABIS SATIVA, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2017 and 2016
3. Fair Value Measurements - continued
As of March 31, 2017, assets and liabilities measured at fair value on a recurring basis were as follows:
|
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
Digital Currency
|
|
$ 18,179
|
|
$ -
|
|
$ 18,179
|
|
$ -
|
|
Total assets measured at fair value - unaudited
|
|
$ 18,179
|
|
$ -
|
|
$ 18,179
|
|
$ -
|
As of December 31, 2016, assets and liabilities measured at fair value on a recurring basis were as follows:
|
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
Digital Currency
|
|
$ 41,191
|
|
$ -
|
|
$ 41,191
|
|
$ -
|
|
Total assets measured at fair value
|
|
$ 41,191
|
|
$ -
|
|
$ 41,191
|
|
$ -
|
4. Hempcoins
At March 31, 2017 and December 31, 2016, the Company has possession of approximately 110,000,000 Hempcoins. Hempcoins are reported as digital currency. Every 10 Hempcoins are backed by 1 share of Rocky Mountain Inc (RMTN). At March 31, 2017 and December 31, 2016 the value of Hempcoins was $2,375 and $14,911, respectively, computed by converting first to bitcoin and then to US Dollars. (See Note 1). 100,000,000 hempcoins were contributed to the Company in 2015 by a director with a cost basis of $4,731. Approximately 10,000,000 were earned by the Company during 2015 with a cost basis of $207.
5. Garycoins
At March 31, 2017 and December 31, 2016, the Company has possession of 900,005,098 cryptocurrency coins named “President Johnson” trading under symbol “GARY,” which were contributed to the Company by a director during 2016 with a cost basis of $5,931. President Johnson coins are reported as digital currency. At March 31, 2017 and December 31, 2016 the value of these coins was estimated to be $15,804 and $26,280, respectively, computed by converting to a bitcoin value in US Dollars. (See Note 1).
6.
Investment in Joint Venture
On September 11, 2015, Hi-Brands International, Inc. a wholly owned subsidiary of the Company entered into a joint venture agreement with I.D.E.A – International Dental Emergency Alliance, LLC. (IDEA). IDEA is the developer of a pharmacy discount card distribution and online marketing platform with access to a network of approximately 60,000 participating pharmacies through a virtual and/or physical discount card. IDEA and the Company wish to develop, market and distribute a private label discount card and system under its proprietary brands and/or trademarks to the general public and to sub-distributors. The Company and IDEA have agreed to share all revenues 50/50 and IDEA has agreed to pay the Company 50% of a $0.50 shared fee per claim. The claim fee will increase based upon a set schedule as claims increase. The term of the agreement is for 3 years, but can be renewed for an additional three (3) year term periods. IDEA is charging the Company a set up fee and as part of the agreement IDEA is expected to generate 25,000 members/cardholders in the first year.
CANNABIS SATIVA, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2017 and 2016
The Company entered into a convertible note payable with IDEA for payment of the $35,000 set-up fee. The convertible note and accrued interest were convertible into shares of the Company’s common stock at a variable conversion price equal to 40% multiplied by the average of the 3 highest and 2 lowest trading days in the 10-day period preceding conversion. In addition, the note contains an antidilution feature in which the conversion price could further adjust if the Company sells equity securities at an effective price less than the current conversion price, as defined. The maturity date of the note was January 2, 2017. The note bore interest at 10%. IDEA converted the note into 30,000 shares in April 2016. In December 2016, the Company issued an additional 30,000 as compensation to IDEA, which were valued at approximately $150,000 based on the closing price on such date and recorded as interest expense.
6.
Investment in Joint Venture – continued
During the year ended December 31, 2015, the Company recorded the initial derivative liability of $83,000 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of $0.92, stock price on the date of grant of $2.31, expected dividend yield of 0%, expected volatility of 179%, risk free interest rate of 0.50% and expected term of 2 years. The change in fair value during the three months ended March 31, 2016 was insignificant.
Upon initial valuation, the derivative liability exceeded the face value of the convertible note payable by approximately $48,000, which was recorded as a day one loss on derivative liability. Subsequent remeasurements were based on the following assumptions at December 31, 2015 and April 20, 2016 (date of conversion): exercise prices of $0.28 and $2.05, stock price on the valuation date of $0.70 and $5.12, expected dividend yield of 0% and 0%, expected volatility of 134% and 169%, risk free interest rate of 0.50% and 0.50% and expected terms of 2 and 2 years, respectively. Upon conversion, the Company reclassified approximately $83,000 to additional paid-in capital related to the convertible note.
7. Intangibles
Intangible assets consisted
of the following at March 31, 2017 and December 31, 2016:
|
|
Unaudtied
|
|
|
|
March 31,
|
December 31,
|
|
|
2017
|
2016
|
|
|
|
|
|
CBDS.com website (Cannabis Sativa)
|
$ 13,999
|
$ 13,999
|
|
Intellectual Property Rights (Cannabis Sativa)
|
2,894,250
|
2,894,250
|
|
Intellectual Property Rights (iBudtender)
|
400,000
|
400,000
|
|
Patents and Trademarks (Cannabis Sativa)
|
17,348
|
17,348
|
|
Patents and Trademarks (Wild Earth)
|
4,425
|
4,425
|
|
|
3,330,022
|
3,330,022
|
|
Less: Accumulated Amortization
|
481,404
|
389,054
|
|
|
|
|
|
Net Intangible Assets
|
$ 2,848,618
|
$ 2,940,968
|
Amortization expense for the three months ended March 31, 2017 and 2016 was $92,350 and $12,762 respectively. Amortization for each of the next 5 years is $355,660 annually.
Goodwill of $247,051 consisted of the acquisition of iBudtender (see Note 10) at March 31, 2017 and December 31, 2016, respectively.
CANNABIS SATIVA, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2017 and 2016
8. Related Parties
The Company has receivedadvances from related parties and officers of the Company to cover operating expenses. At March 31, 2017 and December 31, 2016, net amounts due to the related parties were $451,879. One of the notes payable is convertible at a fixed price of $2.42 During the three months ended March 31, 2017 and 2016, the Company has imputed interest on these notes at the rates between 5% and 8% per annum and has recorded interest expense related to these balances in the amount of $5,649 and $548, respectively. Because the related parties do not expect the imputed interest to be repaid, the interest has been recorded as a contribution of capital.
At March 31, 2017 and December 31, 2016 the Company has a note receivable from a related party in the amount of $15,742 and $15,000, respectively, which is due on demand.
9. Stockholders’ Equity
Preferred Stock
The Company is authorized to issue up to 5,000,000 shares of preferred stock. The Company designated and determined the rights of Series A preferred stock (“Series A”) with a par value of $0.001. The Company is authorized to issue 5,000,000 shares of Series A. The holders of Series A are entitled to dividends if the Company declares a dividend on common shares, have no liquidation preference, have voting rights equal to 1 vote per share, and can be converted into one share of common.
Common Stock
During the year ended December 31, 2016 the board of directors approved the issuance of 1,077,433 shares of common stock for services in the amount of $2,721,150. Approximately $417,000 was recorded as prepaid consulting due to the non-forfeitable nature of the shares issued. During the three months ended March 31, 2017, the Company amortized approximately $85,417 to professional fees in the accompanying consolidated statement of operations.
During the year ended December 31, 2016 the board of directors approved the issuance of 150,000 shares of common stock to purchase iBudtender Inc., with a fair value of $300,000 (see Note 10). At March 31, 2017 and December 31, 2016, 50,000 shares have yet to be issued.
The Company approved a Private Placement Memorandum on October 14, 2016. The total offering proceeds can be up to $1,500,000 by offering 625,000 of the Company’s stock at $2.40 per share. Each unit will consist of 1 (one) share of common stock and 1 (one) warrant. Each warrant entitles the holder to purchase 1(one) common share at the exercise price of $4.00 which expire in January 2020. The offering terminated on December 14, 2016 but can be extended for up to 60 additional days. At March 31, 2017 and December 31, 2016, the Company had received $356,100 and $197,730, respectively, for a total of $553,830. At March 31, 2017all the stock had been issued to investors as required, 230,775 shares common stock. At December 31, 2016 no stock had yet been issued. Such amount was included in stock subscriptions payable in the accompanying balance sheet at December 31, 2016.
During the three months ended March 31, 2017 the board of directors approved the issuance of 300,000 shares of common stock for services in the amount of $1,653,000. The fair value of the shares issued was based on the market price of the Company’s common stock on the measurement date.
During the three months ended March 31, 2017 a related party purchased 80,000 shares common stock for $415,136 in cash.
CANNABIS SATIVA, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2017 and 2016
10. Purchase of iBudtender Inc.
On August 8, 2016, the Company purchased 50.1% interest in iBudtender Inc. The Company paid iBudtender $50,000 and agreed to issue iBudtender 150,000 shares of common stock, of which 100,000 were issued at closing and 50,000 are to be issued 180 days from closing. In exchange, iBudtender issued 5,010,000 shares of its common stock to the Company. Since this was not a significant acquisition, the Company did not file an Amended 8K.
The following summarizes the transaction with iBudtender at closing on August 8, 2016:
|
Cash
|
$ 5,635
|
|
Intellectual Property
|
400,000
|
|
Goodwill
|
247,051
|
|
Total Assets
|
$ 652,686
|
|
|
|
|
Fair value of NCI
|
(239,281)
|
|
Notes Payable – Related Parties
|
(63,405)
|
|
|
|
|
Net Purchase
|
$ 350,000
|
In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired assets such as a business to consumer web portal and app, analyses of historical financial performance of the products and estimates of future performance of the products and intellectual properties acquired. The fair values of the identified intangible assets related to Intellectual Property and Goodwill and the Company has preliminarily recorded the purchase price as an intangible asset and such asset is being amortized over its estimated useful life of 10 years. During 2014 and 2015, the Company utilized an amortization period of 20 years, but based on a change in estimate and the evolving industry, the Company is utilizing a useful life of 10 years. The purchase price allocation is subject to completion of the Company’s analysis of the fair value of the assets acquired as of the date of the acquisition. Any related adjustment is not expected to be material. The final valuation is expected to be completed as soon as practicable but no later than one year from the closing of the transaction. The fair value of the non-controlling interest is based on the estimated fair value, net of discounts for lack of marketability and control. The establishment of the allocation to goodwill and identifiable intangible assets requires the extensive use of accounting estimates and management judgment. The fair values assigned to the assets acquired are based on estimates and assumptions from data currently available.
The following table sets forth the components of identified intangible assets associated with the Acquisition and its estimated useful life:
|
|
|
Fair Value
|
|
Useful Life
|
|
Technology: Website & App
|
$
|
400,000
|
|
15 Years
|
|
|
|
|
|
|
CANNABIS SATIVA, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
For the Three Months Ended March 31, 2017 and 2016
11. Going Concern Considerations
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying consolidated financial statements, the Company has negative working capital, has incurred operating losses since inception, and has not yet produced significant continuing revenues from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern. Management anticipates that it will be able to raise additional working capital through the issuance of stock and through additional loans from investors.
The ability of the Company to continue as a going concern is dependent on its ability to raise adequate capital to fund operating losses until it is able to engage in profitable business operations. To the extent financing is not available, the Company may not be able to, or may be delayed in, developing its services and meeting its obligations. The Company will continue to evaluate its projected expenditures relative to its available cash and to evaluate additional means of financing in order to satisfy its working capital and other cash requirements. The accompanying financial statements do not reflect any adjustments that might result from the outcome of these uncertainties.
12. Commitments and Contingencies
The Company leases an office and warehouse facility in Mesquite, Nevada that serves as the principal executive offices and provides manufacturing and warehouse space. The leased space consists of 908 square feet. Rent expense for the three months ended March 31, 2017 and 2016 was $2,936 and $2,315, respectively. On March 1, 2017, a new lease agreement was signed at a monthly rate of $1,392. Lease term is for 12 (twelve) months with a renewal option available for an additional 12 (twelve) months.
Litigation
In the ordinary course of business, we may face various claims brought by third parties and we may, from time to time, make claims or take legal actions to assert our rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject us to litigation. Management believes the outcomes of currently pending claims are not likely to have a material effect on our consolidated financial position and results of operations.
In May 2015, a suit was brought against the Company by a subcontractor for non-payment of services. In April 2017, the pending litigation was settled for $19,000, which the Company had accrued.
13. Subsequent Events
Common Stock Issued for Services
During the period from April 1, 2017 through May 1, 2017, 143,169 restricted shares were issued for services.
Acquisition
In April 2017, the Company purchased intellectual property associated with the White Rabbit line of cannabis products, for $150,000 and 10,000 shares of the Company’s common stock
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.
Cannabis Sativa, Inc., together with its subsidiaries, are collectively referred to “Cannabis Sativa”, the “Company”, “us”, “we”, or “our”. The following information should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this report. For additional context with which to understand our financial condition and results of operations, see the discussion and analysis included in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission (“SEC”) on May 5, 2017, as well as the consolidated financial statements and related notes contained therein.
Forward Looking Statements
Certain statements in this report, including information incorporated by reference, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements reflect current views about future events and financial performance based on certain assumptions. They include opinions, forecasts, intentions, plans, goals, projections, guidance, expectations, beliefs or other statements that are not statements of historical fact. Words such as “may,” “should,” “could,” “would,” “expects,” “plans,” “believes,” “anticipates,” “intends,” “estimates,” “approximates,” “predicts,” or “projects,” or the negative or other variation of such words, and similar expressions may identify a statement as a forward-looking statement. Any statements that refer to projections of our future financial performance, our anticipated growth and trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results and the development of our products, are forward-looking statements.
Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include those discussed in this Quarterly Report on Form 10-Q. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We file reports with the SEC. You can read and copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.
Corporate History
We were incorporated under the laws of Nevada in November 2005. We acquired a wholly-owned subsidiary named Kush, a Nevada corporation, in June 2014 in exchange for shares of our common stock. Since November 2015, Kush has been spun off and is no longer a subsidiary of the Company. Our wholly-owned subsidiary Wild Earth Naturals, Inc. ("Wild Earth") was acquired by us in July 2013 in exchange for shares of our common stock. We acquired a 50.1% interest in our subsidiary iBudtender, Inc., including its wholly owned subsidiary iBudtender, LLC, a California limited liability company (collectively, “iBudtender”) in August of 2016 in exchange for cash and shares of our common stock. From our inception through September 30, 2013, we were engaged in the tanning salon business and operated a tanning salon in Saratoga Springs, Utah under the name "Sahara Sun Tanning." As a result of our acquisition of Wild Earth in July 2013, we became engaged in the herbal skin care products business. On September 30, 2013, we sold the assets of the tanning salon business to a third party.
Description of Our Business
We are engaged in the research, development, acquisition and licensing of specialized natural cannabis related products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. We also are engaged in marketing and branding within the cannabis space, including with our trademark pending “hi” brand and others. We hold a license for a proprietary cannabis lozenge delivery methodology, and a proprietary cannabis trauma cream formula. We have recently been awarded a U.S. patent for a strain of cannabis plant named Ecuadorian Sativa (also referred to as CTS-A or CTA). We also have U.S. patents pending on cannabis based compositions and methods of treating hypertension and a lozenge delivery system.
Our Strategy
We plan to license our intellectual property, including patents, branding and know-how to companies licensed under, and in full compliance with, state regulations applicable to cannabis businesses. We also plan to market certain products and to control the quality of our products beginning at the formulation stage and continuing through controlled sourcing of raw ingredients, manufacturing, packaging, and labeling. We will continue to support and prosecute our pending patents, and to develop and acquire new patents, trade secrets, trademarks and other intellectual property. In addition, we will seek new branding and licensing opportunities for our intellectual property and we will seek strategic corporate and product acquisitions.
Results of Operations
Three Months Ended March 31, 2017 Compared With Three Months Ended March 31, 2016
Revenue for the fiscal quarters ended March 31, 2017 and 2016 was $1,065 and $2,024, respectively. Cost of revenues for the fiscal quarters ended March 31, 2017 and 2016 was $1,099 and $579, respectively. Gross profit (loss) for the fiscal quarters ended March 31, 2017 and 2016 was $(34) and $1,445, respectively. Net loss for the fiscal quarter ended March 31, 2017 was $2,030,380 compared to net loss of $321,475 for the fiscal quarter ended March 31, 2016.
Total operating expenses were $2,007,334 for the fiscal quarter ended March 31, 2017 and $331,927 for the fiscal quarter ended March 31, 2016. The increase of $1,675,407 was due primarily to an increase of $1,596,219 in professional fees related to the development of business transactions for the Company. The bulk of the expenses for both quarters were non-cash transactions. In the first quarter of 2017, the primary non-cash transaction was stock issued for services in the amount of $1,653,000. In the first quarter of 2016, the primary non-cash transaction was also stock issued for services in the amount of $179,624. Despite the large net loss amounts for both quarters, because of non-cash transactions, the net cash used in operating activities was $141,750 for the quarter ended March 31, 2017 and $50,543 for the quarter ended March 31, 2016.
Liquidity and Capital Resources
As stated above, our operations used $141,750 in cash for the quarter ended March 31, 2017. During the same quarter, financing activities provided cash of $771,236. Cash provided by financing activities during the quarter ended March 31, 2017, came from cash proceeds from the sale of stock in the amount of $415,136 and cash proceeds from a private offering of stock in the amount of $356,100.
As stated above, our operations used $50,543 in cash for the quarter ended March 31, 2016. During the same quarter, financing activities provided cash of $56,500. Cash provided by financing activities during the first quarter of 2016, came from cash proceeds from related parties in the amount of $56,500.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As stated above, we incurred net loss of $2,030,380 and $321,475, respectively, for the quarters ended March 31, 2017 and 2016 and had an accumulated deficit of $61,235,463 as of March 31, 2017. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. The Company has also issued an aggregate of 230,775 warrants which expire on January 31, 2020. Each warrant is for the purchase of one share of common stock of the Company at the exercise price of $2.00 per share. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.
As of May 18, 2017, the Company had cash on hand of $563,824. Much of the cash came from financing activities during the first quarter of 2017. As a result, the Company believes it has sufficient liquidity to meet the immediate needs of our current operations.
Off Balance Sheet Arrangements
None
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Not required.
Item 4. Controls and Procedures.
Disclosure Controls and Procedures
Under the supervision and with the participation of our management including our chief executive officer and our chief financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of the end of the period covered by this report. Based upon that evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective such that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding disclosure.
Based on its evaluation, our management concluded that there are material weaknesses in our internal control over financial reporting as follows: lack of timely closing of books and ability to get accounting information and schedules to our auditors in a timely manner. A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
Management identified the following material weaknesses:
We have not performed a risk assessment and mapped our processes to control objectives;
We have not implemented comprehensive entity-level internal controls;
We have not implemented adequate system and manual controls;
We did not employ an adequate number of people to ensure a control environment that would allow for the
accurate and timely reporting of the financial statements in accordance with GAAP; and
We do not have sufficient segregation of duties.
Based on our evaluation under the frameworks described above, our management has concluded that our internal control over financial reporting was not effective as of March 31, 2017. However, moving forward with the intended addition of additional staff, we believe our current framework will help remedy our material weaknesses.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings.
We are not a party to any material legal proceedings and, to the best of our knowledge, no such legal proceedings have been threatened against us.
Item 1A. Risk Factors
Not required.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
The board of directors approved a Private Placement Memorandum (“PPM”) on October 14, 2016, pursuant to which the Company would conduct a private placement of units. The PPM offered 625,000 units at $2.40 per unit. Each unit consisted of one share of common stock and one warrant. Each warrant entitles the holder to purchase one share of common stock at an exercise price of $2.00. The warrants expire on January 31, 2020. The offering terminated on January 31, 2017. During the quarter ended March 31, 2017, the Company issued 230,775 shares of common stock and warrants subscribed for under the PPM in exchange for $553,830, of which $356,100 was received during the three months ended March 31, 2017.
During the quarter ended March 31, 2017, the Company issued 300,000 shares of common stock for services. The shares had a fair value of $1,653,300.
During the quarter ended March 31, 2017, a related party purchased 80,000 shares of common stock for $415,136.
Each of the issuances of stock set forth above in this Item 2 was exempt from the registration requirements of Section 5 of the Securities Act of 1933 pursuant to Section 4(2) of the Act since the issuance of the shares did not involve any public offering.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
None.
Item 6. Exhibits.
The following documents are included as exhibits to this report:
(a) Exhibits
|
Exhibit
Number
|
|
SEC Reference Number
|
|
Title of Document
|
|
|
|
|
|
|
|
|
|
3.1(1)
|
|
3
|
|
Articles of Incorporation
|
|
|
3.2(1)
|
|
3
|
|
Bylaws
|
|
|
31.1
|
|
31
|
|
Section 302 Certification of Principal Executive Officer
|
|
|
31.2
|
|
31
|
|
Section 302 Certification of Principal Financial Officer
|
|
|
32.1
|
|
32
|
|
SeS Section 1350 Certification of Principal Executive Officer
|
|
|
32.2
|
|
32
|
|
Se SSection 1350 Certification of Principal Financial Officer
|
|
|
101.INS(2)
|
|
|
|
XBRL Instance Document
|
|
|
101.SCH(2)
|
|
|
|
XBRL Taxonomy Extension Schema
|
|
|
101.CAL(2)
|
|
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
101.DEF(2)
|
|
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
|
101.LAB(2)
|
|
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
|
101.PRE(2)
|
|
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
|
|
|
|
|
|
|
(1) Incorporated by reference to Exhibits 3.01 and 3.02 of the Company's Registration Statement on Form 10 filed January 28, 2009.
(2) XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Cannabis Sativa, Inc.
Date: May 22, 2017
|
By: /s/ Mike Gravel
|
|
Mike Gravel, Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
|
|
|
|
By: /s/ Carolyn Merrill
|
|
Carolyn Merrill, Chief Financial Officer
|
|
(Principal Financial and Accounting Officer)
|